This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Aripiprazole in Adolescents With Schizophrenia (APEX 239)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier:
NCT00102063
First received: January 19, 2005
Last updated: August 6, 2012
Last verified: August 2012
Results First Received: May 11, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Schizophrenia
Interventions: Drug: Aripiprazole tablet, 10 mg
Drug: Aripiprazole tablet, 30 mg
Drug: Placebo tablet

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were recruited from 101 centers in the United States, Europe, South America, the Caribbean, and South Africa between August 2004 and August 2006.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Participants were screened over a 4-week period.

Reporting Groups
  Description
Aripiprazole 10 mg/Day Group Dose was titrated to a target dose of 10 mg/day as follows: starting dose 2 mg/day, increased to 5 mg/day on Day 3, 10 mg/day on Day 5; one dose reduction to 5 mg/day allowed after Day 25
Aripiprazole 30 mg/Day Group Dose was titrated to a target dose of 30 mg/day as follows: starting dose 2 mg/day, increased to 5 mg/day on Day 3, 10 mg/day on Day 5, 15 mg/day on Day 7, 20 mg/day on Day 9, and 30 mg/day on Day 11; one dose reduction to 15 mg/day allowed after Day 25
Placebo Group Participants were given a single pill administered once daily

Participant Flow:   Overall Study
    Aripiprazole 10 mg/Day Group   Aripiprazole 30 mg/Day Group   Placebo Group
STARTED   100   102   100 
COMPLETED   84   84   90 
NOT COMPLETED   16   18   10 
Lack of Efficacy                5                1                1 
Adverse Event                7                4                2 
Withdrawal by Subject                4                12                5 
Lost to Follow-up                0                0                1 
Protocol Violation                0                1                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Aripiprazole 10 mg/Day Group Dose was titrated to a target dose of 10 mg/day as follows: starting dose 2 mg/day, increased to 5 mg/day on Day 3, 10 mg/day on Day 5; one dose reduction to 5 mg/day allowed after Day 25
Aripiprazole 30 mg/Day Group Dose was titrated to a target dose of 30 mg/day as follows: starting dose 2 mg/day, increased to 5 mg/day on Day 3, 10 mg/day on Day 5, 15 mg/day on Day 7, 20 mg/day on Day 9, and 30 mg/day on Day 11; one dose reduction to 15 mg/day allowed after Day 25
Placebo Group Participants were given a single pill administered once daily
Total Total of all reporting groups

Baseline Measures
   Aripiprazole 10 mg/Day Group   Aripiprazole 30 mg/Day Group   Placebo Group   Total 
Overall Participants Analyzed 
[Units: Participants]
 100   102   100   302 
Age 
[Units: Years]
Mean (Standard Deviation)
 15.6  (1.3)   15.4  (1.4)   15.4  (1.4)   15.5  (1.4) 
Gender 
[Units: Participants]
       
Female   55   37   39   131 
Male   45   65   61   171 
Race (NIH/OMB) 
[Units: Participants]
       
American Indian or Alaska Native   0   0   1   1 
Asian   16   12   15   43 
Native Hawaiian or Other Pacific Islander   0   0   0   0 
Black or African American   17   11   6   34 
White   54   62   64   180 
More than one race   0   0   0   0 
Unknown or Not Reported   13   17   14   44 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in Positive and Negative Syndrome Scale (PANSS) Total Score   [ Time Frame: Baseline and Day 42 ]

2.  Secondary:   Change in Positive and Negative Syndrome Scale (PANSS) Positive Subscale Score   [ Time Frame: Baseline and Day 42 ]

3.  Secondary:   Change in Positive and Negative Syndrome Scale (PANSS) Negative Subscale Score   [ Time Frame: Baseline and Day 42 ]

4.  Secondary:   Change in Clinical Global Impression (CGI) Severity Score   [ Time Frame: Baseline and Day 42 ]

5.  Secondary:   Clinical Global Impression (CGI) Improvement Score   [ Time Frame: Baseline and Day 42 ]

6.  Secondary:   Change in Children’s Global Assessment Scale (CGAS) Score   [ Time Frame: Baseline and Day 42 ]

7.  Other Pre-specified:   Change in Pediatric Quality of Life Enjoyment and Satisfaction (PQLES) Questionnaire Total Score   [ Time Frame: Baseline and Day 42 ]

8.  Other Pre-specified:   Patients Achieving Remission   [ Time Frame: Baseline and Day 42 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Margaretta Nyilas
Organization: Otsuka Pharmaceutical Development & Commercialization, Inc.
phone: 609-452-5673
e-mail: Margaretta.nyilas@otsuka-us.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier: NCT00102063     History of Changes
Other Study ID Numbers: 31-03-239
Study First Received: January 19, 2005
Results First Received: May 11, 2012
Last Updated: August 6, 2012